Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Trial Profile

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs PXVX 0200 (Primary)
  • Indications Cholera
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Jul 2018 Planned number of patients changed from 10 to 50.
    • 17 Jul 2018 Planned End Date changed from 30 Nov 2018 to 30 Nov 2021.
    • 17 Jul 2018 Planned primary completion date changed from 31 Dec 2018 to 30 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top